Collecting blood from pregnant women to develop a prenatal test for Down syndrome
Collects blood from pregnant women to help develop a prenatal test for Down syndrome.
Key facts
- Who runs it
- Sequenom, Inc.
- Where
- Birmingham, Camden, Charleston, Chicago, Detroit, Grand Rapids, Iowa City, Los Angeles, and San Diego, United StatesSee the 12 sitesAlso in 1 other country, 2 sites
- Trial code
- Registry title
- Specimen Collection From Pregnant Women at Increased Risk for Fetal Aneuploidy
- Status
- Recruiting
- People taking part
- 2,000 people, planned
- Started
- May 2011
- Expected to end
- Mar 2028
- Type of study
- Observational
- Record updated
- 9 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for pregnant women whose baby has a higher chance of a chromosome problem. They give blood samples to help build a blood test for T21 (Down syndrome) during pregnancy.
- Age
- 18 years or older
- Sex
- Women only
- Disease stage
- Pregnant between 10 and 22 weeks, with a higher chance that the baby has a chromosome abnormality (fetal aneuploidy).
Main reasons for not taking part
- The baby has died at the time the sample is taken
- Already gave a sample in this trial
- Not willing to have a CVS and/or amniocentesis (tests that take a sample from the womb) for genetic testing
- Not willing to share the genetic results of that test
This trial only enrols pregnant participants. The registry sentence this rests on: * pregnant between 10 and 22 weeks gestation
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- pregnant between 10 and 22 weeks gestation
- 18 years of age or older
- provides signed and dated informed consent
- subject is at increased risk for fetal aneuploidy
- subject is willing to undergo a CVS and/or amniocentesis procedure for the purpose of genetic analysis
- subject agrees to provide the genetic results of the invasive procedure
Who cannot take part
- Previous sample donation under this protocol
- Fetal demise at time of specimen sampling
Where in United States
Also in 1 other country, 2 sites
- University of Alabama BirminghamBirmingham, United StatesContact: Rachel CopperTaking people
- The Cooper Health SystemCamden, United StatesContact: Clare HansonTaking people
- Medical University of South CarolinaCharleston, United StatesContact: Betty OswaldTaking people
- Reproductive Genetics InstituteChicago, United StatesContact: Denise GinsbergTaking people
- Henry Ford HospitalDetroit, United StatesContact: Ellen MartindellTaking people
- Spectrum HealthGrand Rapids, United StatesContact: Yvonne EdgerlyTaking people
- University of Iowa Health CareIowa City, United StatesContact: Diedre FleenerTaking people
- Cedars-Sinai Medical CenterLos Angeles, United StatesContact: Deebra Smith, MDTaking people
- Sharp-Rees Stealy Medical GroupSan Diego, United StatesContact: Mary LaPageTaking people
- Specialty Obstetrics of San DiegoSan Diego, United StatesContact: Deborah MaloneTaking people
- UCSDSan Diego, United StatesContact: Jason ChibuckTaking people
- Women's Health Care ResearchSan Diego, United StatesContact: Nora MartinezTaking people
About the trial
What the trial wants to find out
The specimen collection is designed for the purpose of the development of a noninvasive prenatal test for T21.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Collection of Whole Blood Specimens From Pregnant Women at Increased Risk of Fetal Chromosomal Abnormality for Use in Development of a Noninvasive Prenatal Test in the Detection of the Relative Quantity of Chromosomal Material in Circulating Cell-Free DNA Extracted From Maternal Plasma
- Plain-language title
- Collecting blood from pregnant women to develop a prenatal test for Down syndromeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 9 September 2026